Advice

in the absence of a submission from the holder of the marketing authorisation:

ramucirumab (Cyramza®) is not recommended for use within NHSScotland.

Indication under review: As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of ≥ 400 ng/mL and who have been previously treated with sorafenib.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice357KB (PDF)

Download

Medicine details

Medicine name:
ramucirumab (Cyramza)
SMC ID:
SMC2246
Indication:
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
11 November 2019